BioDelivery Sciences International, Inc. (BDSI)
|Net Income (ttm)||84.86M|
|52-Week Range||2.50 - 5.62|
|Price Target||5.48 (-2.0%)|
|Earnings Date||May 4, 2022|
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally ... [Read more...]
In 2021, BDSI's revenue was $166.70 million, an increase of 6.54% compared to the previous year's $156.47 million. Earnings were $84.86 million, an increase of 230.05%.Financial Statements
According to 13 analysts, the average rating for BDSI stock is "Buy." The 12-month stock price forecast is 5.48, which is a decrease of -1.97% from the latest price.
Here is how BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults
BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates ...
NEW ORLEANS, Feb. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioDelivery Sciences International, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - February 15, 2022) - Rigrodsky Law, P.A. is investigating BioDelivery Sciences International, Inc. ("BioDelivery") (NASDAQ: BDSI) regarding possible breaches of f...
NEW YORK, Feb. 15, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioDelivery Sciences International, Inc...
Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.
Today, a big takeover announcement has sent shares of BioDelivery and BDSI stock soaring more than 50% on investor enthusiasm for this deal. The post BDSI Stock Alert: The Deal Sending Little-Known BioD...
Markets opened lower on Monday morning, but nothing held these two companies back.
BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is F...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Collegium Pharmaceutical, Inc. f...
Shareholder Alert: Ademi LLP investigates whether BioDelivery Sciences International, Inc. has obtained a Fair Price ...
MILWAUKEE, Feb. 14, 2022 /PRNewswire/ -- Ademi LLP is investigating BioDelivery Sciences (NASDAQ: BDSI) for possible breaches of fiduciary duty and other violations of law in its transaction with Colleg...
Collegium Pharmaceutical Inc (NASDAQ: COLL) will acquire BioDelivery Sciences International Inc (NASDAQ: BDSI) at $5.60 per share in an all-cash transaction, corresponding to an equity value of approxim...
Shares of BioDelivery Sciences International Inc. BDSI, -1.62% blasted 51.7% higher to pace all premarket gainers Monday, after the specialty pharmaceutical company with a portfolio of pain and neurolog...
Transaction is valued at $5.60 per share representing a total equity value of $604 million
BioDelivery (BDSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Let's see if BioDelivery (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.
Shares of the small pharmaceutical company, which focuses on pain management, have been rising since it released updated guidance late last week.
BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.
The biotech company received a favorable court ruling regarding its lead therapy.
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032
RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex...
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?
BioDelivery (BDSI) delivered earnings and revenue surprises of 16.67% and -2.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year